JINYU BIO-TECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.91 CNY | -2.20% |
|
+1.14% | -17.27% |
| Apr. 25 | Jinyu Bio-technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 27 | Taihe Technologies' Chief Financial Officer Resigns | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 19,431 | 21,083 | 23,527 | 18,287 | 9,846 | 9,688 | 9,688 | - |
| Enterprise Value (EV) 1 | 19,431 | 20,015 | 22,011 | 16,954 | 8,451 | 10,000 | 8,348 | 8,378 |
| P/E ratio | 25.2 x | 93.6 x | 58 x | 48.1 x | 47.4 x | 41.4 x | 28.2 x | 20.2 x |
| Yield | 2.11% | 0.32% | 0.57% | 0.67% | 0.67% | 0.74% | 1.12% | 1.64% |
| Capitalization / Revenue | 10.2 x | 18.7 x | 14.9 x | 10.3 x | 6.44 x | 7.33 x | 5.3 x | 3.89 x |
| EV / Revenue | 10.2 x | 17.8 x | 13.9 x | 9.54 x | 5.53 x | 6.26 x | 4.57 x | 3.36 x |
| EV / EBITDA | 19.7 x | 55.4 x | 33.8 x | 30 x | 18.6 x | 19.8 x | 14.9 x | 11.6 x |
| EV / FCF | - | - | - | - | - | 70.6 x | 47.7 x | 30.9 x |
| FCF Yield | - | - | - | - | - | 1.42% | 2.1% | 3.23% |
| Price to Book | 3.86 x | 4.54 x | 4.72 x | 3.49 x | 1.99 x | 2.25 x | 1.76 x | 1.65 x |
| Nbr of stocks (in thousands) | 1,170,537 | 1,126,240 | 1,126,240 | 1,118,482 | 1,092,777 | 1,087,368 | 1,087,368 | - |
| Reference price 2 | 16.60 | 18.72 | 20.89 | 16.35 | 9.010 | 8.910 | 8.910 | 8.910 |
| Announcement Date | 4/28/19 | 3/29/20 | 4/22/21 | 4/21/22 | 4/20/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,897 | 1,127 | 1,582 | 1,776 | 1,529 | 1,598 | 1,827 | 2,490 |
| EBITDA 1 | 986.4 | 361.1 | 651.9 | 565.5 | 454.3 | 503.9 | 559.2 | 722.9 |
| EBIT 1 | 889.2 | 253.6 | 477.8 | 414.7 | 255.1 | 315.2 | 401.4 | 570.6 |
| Operating Margin | 46.89% | 22.51% | 30.2% | 23.34% | 16.69% | 19.72% | 21.97% | 22.92% |
| Earnings before Tax (EBT) 1 | 889.3 | 253.5 | 476.2 | 413.3 | 245.6 | 315.8 | 404 | 575.4 |
| Net income 1 | 754.5 | 221 | 406.2 | 382.3 | 210.7 | 283.6 | 351.7 | 493.2 |
| Net margin | 39.78% | 19.62% | 25.68% | 21.52% | 13.78% | 17.75% | 19.25% | 19.81% |
| EPS 2 | 0.6600 | 0.2000 | 0.3600 | 0.3400 | 0.1900 | 0.2600 | 0.3164 | 0.4405 |
| Free Cash Flow 1 | - | - | - | - | - | 141.7 | 175 | 271 |
| FCF margin | - | - | - | - | - | 8.86% | 9.58% | 10.88% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 28.11% | 31.29% | 37.49% |
| FCF Conversion (Net income) | - | - | - | - | - | 49.95% | 49.76% | 54.94% |
| Dividend per Share 2 | 0.3500 | 0.0600 | 0.1200 | 0.1100 | 0.0600 | 0.0800 | 0.1000 | 0.1459 |
| Announcement Date | 4/28/19 | 3/29/20 | 4/22/21 | 4/21/22 | 4/20/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 S1 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 437.9 | - | 420.3 | 364 | - | 534.3 | 379.2 | 347.9 | 380 | 590 | 532 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | -39.5 | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | -9.02% | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | 104.9 | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - |
| EPS | -0.0300 | 0.0900 | - | - | 0.0200 | 0.1400 | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/21/22 | 8/29/22 | 4/20/23 | 4/20/23 | 8/24/23 | 10/30/23 | 4/25/24 | 4/25/24 | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,068 | 1,516 | 1,334 | 1,395 | 1,711 | 1,340 | 1,311 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | - | 142 | 175 | 271 |
| ROE (net income / shareholders' equity) | 15.6% | 4.49% | 8.37% | 7.39% | 3.96% | 5.43% | 6.29% | 8.48% |
| ROA (Net income/ Total Assets) | 12.6% | 3.72% | 6.85% | 5.94% | - | 5.25% | 5.1% | 7.26% |
| Assets 1 | 5,998 | 5,950 | 5,932 | 6,441 | - | 5,784 | 6,896 | 6,796 |
| Book Value Per Share 2 | 4.300 | 4.130 | 4.420 | 4.680 | 4.530 | 4.790 | 5.060 | 5.380 |
| Cash Flow per Share 2 | 0.3600 | 0.3600 | 0.6200 | 0.4700 | 0.3100 | 0.3700 | 0.3700 | 0.3400 |
| Capex 1 | 545 | 307 | 227 | 372 | 190 | 273 | 282 | 179 |
| Capex / Sales | 28.74% | 27.23% | 14.33% | 20.95% | 12.42% | 17.09% | 15.43% | 7.2% |
| Announcement Date | 4/28/19 | 3/29/20 | 4/22/21 | 4/21/22 | 4/20/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.91
CNY
Average target price
9.38
CNY
Spread / Average Target
+5.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.27% | 1.34B | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -0.68% | 1.4B | |
| -2.73% | 1.26B | |
| -28.16% | 1.2B | |
| -14.67% | 1.12B | |
| -5.37% | 990M | |
| -24.06% | 805M |
- Stock Market
- Equities
- 600201 Stock
- Financials Jinyu Bio-technology Co., Ltd.
